Kamada Ltd. Q2 2026 Earnings Call Summary
Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.
How this was made
The 30-second read
Why it matters
Near-term trading focus is on whether Q4 plasma sales commencement and the $50M plasma supply agreement translate into the expected $200M to $205M revenue range, while longer-dated upside depends on M&A and biosimilar pipeline launches.
Market read
The article provides concrete 2026 guidance assumptions and contract economics that can shift expectations for revenue timing and cash generation.
What to watch
Gross margin is described as mix-dependent, so traders may discount the 26% adjusted EBITDA margin sustainability if product mix shifts or plasma economics change.
Background
Kamada’s Q2 2026 call emphasizes a vertically integrated plasma-to-production model, distribution expansion via biosimilars, and CYTOGAM post-marketing research.
Ticker impact
Kamada reiterated 2026 revenue guidance of $200M to $205M and expects plasma sales to start in Q4, plus a new $50M plasma supply agreement.
Moderate positive bias for the next few sessions as traders price in Q4 plasma commencement and the $17M annual contribution.
The call provides specific forward assumptions (Q4 plasma start) and contract economics ($50M total, ~$17M annually), which can move expectations even without a new earnings print in this summary.
Market effects
Reinforces the plasma collection and vertically integrated biosupply model as a margin-supporting strategy for specialty biotech.
U.S. plasma infrastructure expansion (Houston and San Antonio) may affect regional supply dynamics for plasma-derived products.
Israel and MENA biosimilar/distribution expansion highlights continued geographic diversification for transplant-related therapies.
Counterpoint
The guidance is reiterated rather than raised, and the biggest acceleration driver is still M&A execution, which is uncertain.
Key entities
- companyKamada Ltd.
Subject of the earnings call summary, providing 2026 guidance, plasma supply agreement economics, margin commentary, and CFO transition details.
- productCYTOGAM
Kamada’s transplant-related product referenced for post-marketing research intended to support utilization.
